<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739268</url>
  </required_header>
  <id_info>
    <org_study_id>SeveX2018</org_study_id>
    <nct_id>NCT03739268</nct_id>
  </id_info>
  <brief_title>GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration</brief_title>
  <acronym>SeveX</acronym>
  <official_title>GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the potential GLP-1-mediated contribution to&#xD;
      the well-established glucose-lowering effect of sevelamer-induced bile acid sequestration .&#xD;
      Exendin9-39 has been demonstrated to act as a potent and specific GLP-1 receptor antagonist&#xD;
      with no partial agonistic potential and is considered a useful tool in the assessment of&#xD;
      GLP-1 physiology. The aim is to evaluate any contribution of sevelamer-induced GLP-1&#xD;
      secretion to the reduced plasma glucose concentrations observed after treatment with&#xD;
      sevelamer. A randomised placebo-controlled cross-over study involving two 17-day treatment&#xD;
      periods with sevelamer and placebo, respectively, in metformin-treated patients with type 2&#xD;
      diabetes, will be conducted. The impact of bile acid sequestration on GLP-1 secretion and&#xD;
      effect will be examined during two randomised experimental days after 15 and 17 days of&#xD;
      treatment with sevelamer (1,600 mg three times a day) and placebo, respectively. During each&#xD;
      of these two experimental days, a meal test with concomitant exendin9-39 infusion or placebo&#xD;
      will be performed (for evaluation of any GLP-1-mediated effects). Postprandial plasma glucose&#xD;
      excursion is the primary endpoint, and secondary endpoints include postprandial plasma/serum&#xD;
      excursions of insulin, C-peptide, GLP-1, glucagon, glucose-dependent insulinotropic&#xD;
      polypeptide (GIP), glucagon-like peptide-2 (GLP-2), peptide YY (PYY), oxyntomodulin, ghrelin,&#xD;
      fibroblast growth factor (FGF)-19, FGF-21, C4 (an intermediate in the de novo synthesis of&#xD;
      bile acids), cholecystokinin (CCK), bile acids and plasma lipids. Furthermore, gastric&#xD;
      emptying, gallbladder emptying, liver fat content, appetite and ad libitum food intake will&#xD;
      be examined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma glucose</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Postprandial plasma glucose (PG) excursion (AUC240 min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of glucagon-like peptide-1 (GLP-1)</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of GLP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of glucose-dependent insulinotropic polypeptide (GIP)</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of glucose-dependent insulinotropic polypeptide (GIP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of glucagon-like peptide-2 (GLP-2)</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of glucagon-like peptide-2 (GLP-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of Glucagon</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of Glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of peptide YY (PYY)</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of peptide YY (PYY)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of Insulin and c-peptide</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of Insulin and c-peptide as a insulin/c-peptide ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of Ghrelin</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of Ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of fibroblast growth factor (FGF)-19</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of fibroblast growth factor (FGF)-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of fibroblast growth factor (FGF)-21</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of fibroblast growth factor (FGF)-21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of Bile acids</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of Bile acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of cholecystokinin (CCK)</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of cholecystokinin (CCK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of plasma lipids</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of plasma lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial responses of Amino acids</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Meal response of Amino acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal and paracetamol at 0 minutes</time_frame>
    <description>Gastric emptying measured by paracetamol absorption test. Paracetamol is ingested along with meal, the appearance in blood will be calculated as a measure of gastric emptying.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of gall bladder emptying</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>Gall bladder volumen measured by ultrasound over time after a meal (see time frame below). The rate of gall bladder emptying will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness and fat</measure>
    <time_frame>At initiation and after 15 days of treatment with sevelamer/placebo</time_frame>
    <description>Liver stiffness and fat content measured by fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite measured by visual analog scale</measure>
    <time_frame>-30 minutes to 240 minutes with ingestion of a meal at 0 minutes</time_frame>
    <description>We assessed appetite parameters (hunger, satiety, fullness, prospective food consumption) and well-being, nausea, and thirst by visual analogue scales. Overall appetite score (OAS) will be calculated as (satiety + fullness + (100 - hunger) + (100 - prospective food consumption)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with type 2 diabetes treated with sevelamer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with type 2 diabetes treated with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer</intervention_name>
    <description>Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days</description>
    <arm_group_label>sevelamer</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo powder dissolved in water 1,600 mg three times a day for 17 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes for at least 3 months (diagnosed according to the criteria of the&#xD;
             World Health Organization (WHO))&#xD;
&#xD;
          -  Men and postmenopausal women&#xD;
&#xD;
          -  Metformin applied as the only glucose-lowering drug&#xD;
&#xD;
          -  Caucasian ethnicity&#xD;
&#xD;
          -  Normal haemoglobin&#xD;
&#xD;
          -  Age above 40 years and below 75 years&#xD;
&#xD;
          -  BMI &gt;23 kg/m2 and &lt;35 kg/m2&#xD;
&#xD;
          -  Informed and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase&#xD;
             (ASAT) &gt;2 times normal values) or history of hepatobiliary disorder&#xD;
&#xD;
          -  Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major&#xD;
             intra-abdominal surgery&#xD;
&#xD;
          -  Nephropathy (serum creatinine &gt;150 ÂµM and/or albuminuria)&#xD;
&#xD;
          -  Hypo- or hyperthyroidism&#xD;
&#xD;
          -  Hypo- or hypercalcaemia&#xD;
&#xD;
          -  Hypo- or hyperphosphataemia&#xD;
&#xD;
          -  Active or recent malignant disease&#xD;
&#xD;
          -  Treatment with medicine that cannot be paused for 12 hours&#xD;
&#xD;
          -  Treatment with oral anticoagulants&#xD;
&#xD;
          -  Any treatment or condition requiring acute or sub-acute medical or surgical&#xD;
             intervention&#xD;
&#xD;
          -  Any condition considered incompatible with participation by the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, M.D. PhD</last_name>
    <role>Study Director</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henriette H Nerild, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bile acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

